Prestige BioPharma Limited (KRX:950210)
South Korea flag South Korea · Delayed Price · Currency is KRW
13,020
-190 (-1.44%)
At close: Oct 2, 2025

Prestige BioPharma Income Statement

Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 20212019 - 2020
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2019 - 2020
14,326689.08161.84--
Upgrade
Revenue Growth (YoY)
1978.97%325.77%---
Upgrade
Cost of Revenue
26,56311,29133.94228.95284.85
Upgrade
Gross Profit
-12,237-10,602127.9-228.95-284.85
Upgrade
Selling, General & Admin
23,30719,10858,23154,42216,432
Upgrade
Research & Development
19,12323,414---
Upgrade
Other Operating Expenses
520.591,326---
Upgrade
Operating Expenses
54,34851,636-906.28122,46018,099
Upgrade
Operating Income
-66,585-62,2381,034-122,689-18,384
Upgrade
Interest Expense
-7,626-7,404-950.8-18.85-6.2
Upgrade
Interest & Investment Income
9,13712,40210,4642,729158.22
Upgrade
Earnings From Equity Investments
---16.96--
Upgrade
Currency Exchange Gain (Loss)
2,145-4,232-924.24-1,592-4,620
Upgrade
Other Non Operating Income (Expenses)
7,3976,6934,0342,282414.8
Upgrade
EBT Excluding Unusual Items
-55,533-54,77913,639-119,288-22,437
Upgrade
Gain (Loss) on Sale of Investments
----15,081
Upgrade
Gain (Loss) on Sale of Assets
-6.789.472.12211.59-0.36
Upgrade
Asset Writedown
59,462--15,807-91,573-
Upgrade
Pretax Income
3,923-54,689-2,095-210,649-7,357
Upgrade
Income Tax Expense
-248.48408.68763.28800.6634.08
Upgrade
Earnings From Continuing Operations
4,171-55,098-2,859-211,450-7,391
Upgrade
Minority Interest in Earnings
18,12622,17720,428--
Upgrade
Net Income
22,297-32,92117,569-211,450-7,391
Upgrade
Net Income to Common
22,297-32,92117,569-211,450-7,391
Upgrade
Shares Outstanding (Basic)
6060606052
Upgrade
Shares Outstanding (Diluted)
6060606052
Upgrade
Shares Change (YoY)
0.44%-0.22%-16.46%20.98%
Upgrade
EPS (Basic)
370.20-549.00292.35-3518.53-143.23
Upgrade
EPS (Diluted)
370.20-549.00292.35-3796.17-143.23
Upgrade
Free Cash Flow
-92,877-68,091-108,636-102,336-16,396
Upgrade
Free Cash Flow Per Share
-1542.04-1135.49-1807.71-1702.88-317.73
Upgrade
Gross Margin
-85.42%-79.03%--
Upgrade
Operating Margin
-464.80%-9032.13%639.01%--
Upgrade
Profit Margin
155.64%-4777.60%10855.90%--
Upgrade
Free Cash Flow Margin
-648.33%-9881.47%-67125.45%--
Upgrade
EBITDA
-44,785-45,97112,684-118,822-16,717
Upgrade
EBITDA Margin
--7837.31%--
Upgrade
D&A For EBITDA
21,80116,26711,6503,8671,667
Upgrade
EBIT
-66,585-62,2381,034-122,689-18,384
Upgrade
EBIT Margin
--639.01%--
Upgrade
Advertising Expenses
869.23970.57---
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.